#ESMO26 sacituzumab tirumotecan + pembrolizumab 能否带来持久缓解？顺铂不耐受、既往未治疗的晚期/转移性尿路上癌（mUC）患者更新后的 II 期结果（N=40）。
🔹 经确认的 ORR：68%；DCR：88%
🔹 中位 DOR：19.4 个月
🔹 中位 PFS：11.2 个月；OS 尚未达到
🔹 在 TROP2 和 PD-L1 表达的各亚组中均观察到缓解，但样本量较小。
🔹 3–4 级 TRAEs：65%（4 mg/kg）vs 57%（5 mg/kg）
@UroToday @myESMO
32 浏览 · 1 赞 · 2 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com